Article Sidebar
Published:
Dec 5, 2018DOI:
10.4314/jpb.v15i2.1Keywords:
Article Details
Copyright of articles published shall reside exclusively with the Faculty of Pharmaceutical Sciences, University of Jos.
DECLARATION & COPYRIGHT TRANSFER
I/We the undersigned author(s) of article entitled
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
Declare as follows:
- The manuscript submitted to Journal of Pharmacy & Bioresources is original and has not been and will be published, whole or in part, in print or electronic format, in any other journal. It is also not being currently considered for publication in any journal.
- The submitted manuscript is a joint decision of all the coauthors.
- Each author has participated sufficiently in the work to warrant his or her inclusion in the list of authors. To this end, each author takes responsibility for appropriate portions of the manuscript.
- Authors have obtained necessary approval to carry out the experiments on animals and human subjects. Approval certificates will be furnished, if required by publishers or editors of the journal.
- Authors do not have any conflict of interest (financial or otherwise) other than those declared.
- If the manuscript is accepted for publication, the authors transfer and assign copyright of the article referenced above to Journal of Pharmacy and Bioresources.
Name & Signature of authors
1. 2.
- 4.
- 6.
- 8.
Corresponding authors name address, affiliation and email:
Main Article Content
Compaction characteristics of a micro-structured fillerbinder “Microcrystarcellactose B3” for direct compression tableting
Abstract
A research was conducted to develop and evaluate a highly compressible micro-structured filler- binder for direct compression tableting. Tapioca starch (TS) was annealed, hydrolyzed and coprocessed with α -lactose monohydrate (α-LMH) and microcrystalline cellulose (MCC) to yield a novel microcrystarcellactose (MSCL B3). The powder suspensions were prepared at a concentration of 40 %w/w in five separate conical flasks. The TS granules were annealed for 1 h and subsequently hydrolyzed with α-amylase at 58o and pH 7 for 1, 2, 3, 4, and 5 h respectively. The reaction was terminated and neutralized with 0.1 N HCL and 0.1 N NaOH respectively. The enzyme hydrolyzed starch (EHS) at 3 h, sieved fraction >75-250 μm was coprocessed with α-LMH and MCC and compressed with load ranging from 2.5 to 12.5 KN. MSCL B3 (component ratio of EHS, α-LMH, and MCC ‘35: 35:30’) possessed improved functionality over direct physical mixture of the excipients. The Py (yield values) are: Cellactose (24.2 MNm-2) > MCC (25 MNm-2) > MSCL B3 (50.0 MNm-2) > Starlac (143 MNm-2). The degree of plastic deformation occurring “Pk” are in the following order: MSCL B3 (17.0 MNm-2) = Cellactose ® (17.0 MNm-2) > MCC (18.6 MNm-2) > Starlac® (19.1 MNm-2). MSCL B3 is as good as Cellactose® and more superior in functionality than Starlac® and MCC. The dilution potential for MSCL B3 in PCM and AA tablets were: 45% and 50 % respectively. MSCL B3 can be used to formulate softer tablet of both poorly compressible API and moisture sensitive API
Keywords: Microcrystarcellactose; Coprocessed excipient; Directly compressible excipient; Highly functional fillerbinder; Tapioca starch
